Upgrade to SI Premium - Free Trial

Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few Months

July 20, 2016 9:48 AM
Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments FDA

Next Articles